Track topics on Twitter Track topics that are important to you
Theranexus debuts on Euronext Paris raising €19.6M that will support the development of its pipeline of CNS drugs for narcolepsy, Parkinson’s, Alzheimer’s and neuropathic pain. Theranexu...
FDA-approved labeling includes boxed warning for depression and suicidality, though this is specific for Huntington's disease patients, who are prone...
CD33 inhibiting drug that was yanked from the market in 2010 due to reports of veno-occlusive disease is now fully...
This week's roundup includes Almirall's appointment of a former Sanofi employee as CEO and various other high-level appointments by Axial...
Chinese start-up CARsgen Therapeutics hopes to launch trials in the US for its first-in-class anti-claudin18.2 CAR-T cell therapy. It is...
RETOUR RISQUÉ DES IPO BIOTECHS À PARIS Après une longue pause estivale, la bourse de Paris s’ouvre à nouveau aux biotechs et aux medtechs. La lyonnaise Biom’up va lever 32 à 44 millions d’e...
Theranexus, annonce la délivrance du brevet américain n° US 9,750,734 sur lequel l’entreprise jouit d’une licence exclusive en accord avec le CEA. Intitulé « Use of Flecainide as an anti-con...
We have published hundreds of Theranexus news stories on BioPortfolio along with dozens of Theranexus Clinical Trials and PubMed Articles about Theranexus for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Theranexus Companies in our database. You can also find out about relevant Theranexus Drugs and Medications on this site too.